Publications found:
112,441
Sort by:
External Defibrillator market in India 2011
US$ 950.00
... description of the segments in the defibrillator market in India. The market overview section provides an insight into the market and highlights the market size and growth. Import ...
August 2011
32 pages
Hair Color Market in India 2011
US$ 950.00
... after order is placed. The hair color market in India is driven by growth in the need to not only cover grey hairs and look presentable but also ... also been highlighted. This is followed by an overview of the hair color market in India. The section talks of the market size and growth of the sector and provides ...
August 2011
38 pages
Chinese Auto Industry Report, 2011H1
US$ 500.00
In 2011 H1, China’s automobile output was 9.16 million, increasing by 2.48% YOY, decreasing by 46.36% over that of 2010 H1; China’s automobile sales volume was 9.33 million, increasing by3.35% YOY, de...
August 2011
21 pages
Chinese Construction Industry Report, 2011H1
US$ 500.00
In January-June 2011, China’s construction machinery industry accumulatively achieved the total industrial output value of CNY 312.35 billion, ascending by 43.04% YOY, and realized the sales revenue o...
August 2011
19 pages
Chinese Logistics Industry Report, 2011H1
US$ 500.00
Operations of the logistics industry are closely related to social production and operations and grow with production and sales of commodities. Currently, China’s logistics industry maintains the grow...
August 2011
19 pages
Chinese Power Industry Report, 2011H1
US$ 500.00
In 2011 H1, the power generation capacity and the power consumption in China both maintained rapid growth; influenced by many factors such as rapid growth in demand, deficient water inflow, tight elec...
August 2011
20 pages
Chinese Real Estate Industry Report 2011H1
US$ 500.00
In 2011 H1, China’s real estate development investment was CNY 2.63 trillion, ascending by 32.90% YOY, in which the residence investment was CNY 1.86 trillion, increasing by 36.10%. China’s commercial...
August 2011
18 pages
Eisai - Catalysts Too Weak to Mitigate Key Patent Expiries
US$ 140.00
... Nov-10 and May-13 respectively); together they contributed ~56% of revenue in FY 03/11. Eisai solely depends on catalysts coming out of its pipeline. Following Halaven approval ... , Eisai has three late stage candidates E-2007/ perampanel ...
August 2011
8 pages
Aurobindo - Feeling The Heat of USFDA and Debt
US$ 140.00
We reiterate our Underperform rating on Aurobindo after Q1 FY12 result that remained ... (up by 39% and 20% of total sales) that included a Government of India tender where ARBP did not earn any profit. As expected ... API and formulations) remain at the core of ‘India advantage’. We reduce our target price to Rs.120
August 2011
6 pages
Ranbaxy - When Will The Base Business Stabilize?
US$ 140.00
We reiterate our Market Perform rating on Ranbaxy after the Q2 CY11 result that was in line with our ... about a possible timely launch. Longer term potential of Ranbaxy seems promising with Daiichi-Ranbaxy likely to become the largest generic company in Japan ...
August 2011
6 pages
Cipla - Margin Improvement - A Healthy Sign.
US$ 140.00
... higher than our earnings estimate owing to the sharp improvement in gross margin. The improvement in gross margin (up by 330 bps, Y-o-Y) is largely due to the ... day exclusivity and (2) improvement in margin as contribution from Indore facility increases. For the longer term, CIPLA’s traditional business model ...
August 2011
6 pages
Auto Ancillary Market in China 2011
US$ 1,950.00
... concerning the auto ancillary sector in China. It also discusses the current market trends as players partipating in trade fairs and exhibitions, players making inroads to India, mergers ...
August 2011
31 pages
IPCA- Margin Improvement, Despite Lower Domestic Sales
US$ 140.00
... sales in WHO member countries. We expect several growth drivers for Ipca in the near term. (1) US generics growth even without the ... WHO member countries and branded formulations (3) margin improvement as sales mix improves in favor of formulation sales. We see Ipca as the best bet in the domestic formulations ...
August 2011
5 pages
TAKEDA - Multiple Challenges Blur Future!
US$ 140.00
There are three major concerns for Takeda – 1) Takeda has got European exposure by the Nycomed acquisition, but as both ... is expected. 2) Safety related issues with Actos affects market prospects of Takeda’s key candidate Aloglipin’s combination drug with Actos and, 3) Pipeline ...
August 2011
8 pages
Sun Pharma- Strong Margin Indicates A Strong Product Portfolio
US$ 140.00
Sun Pharma’s Q1 FY12 result was largely in line with our ... performance was not quite upto the mark, however, EBITDA margin improved by 300 bps Q-o-Q (Y-o-Y not relevant owing to launch of ... peers in the pharma space due to its rich, highly probable and yet hidden Para IV pipeline, strong balance sheet, likely ...
August 2011
8 pages
China Freeze Drying System Industry Report, 2011 - 2012
US$ 1,600.00
With the rapid development of pharmaceutical industry in China, the market size of freeze drying equipment continuously expands, which reached RMB2.425 billion in 2009, including the market of cleanin...
August 2011
53 pages
Dishman - Moving away from CRAMS
US$ 140.00
Dishman’s Q1 FY12 result was below our expectations ... Amcis. The standalone EBITDA increased largely driven by sales from disinfectants in India, supply of intermediate of Brilinta to Astra Zeneca and ... most of them (except for Brilinta intermediate supply) coming from its non-CRAM business. On CRAMs part, we see ...
July 2011
5 pages
Lupin - Impact of Thin Pipeline Showing Up
US$ 140.00
... reiterate our Underperform with target price of `360 on Lupin after its Q1FY12 result that reflected a reduction in ... fag end of the quarter impacted the overall performance. We have always remained concerned about Lupin’s thin US pipeline along with a ... higher depreciation to eat into the earnings of Lupin.
July 2011
8 pages
China Retail Industry Report, 2010-2011
US$ 2,000.00
In 2010, the sales of China’s top 100 chain enterprises hit RMB 1.66 trillion, up 21.2% YoY, accounting for 11% of the total retail sales of social consumer goods. In the meantime, the number of store...
July 2011
121 pages
China Tourism Industry Forecast to 2012
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,200.00 Hard Copy: US$ 1,000.00 CD-ROM: US$ 1,000.00 Chinese tourism industry has emerged as a new growth avenue with increasing purchasing...
July 2011
70 pages
China Diabetes Market Analysis
US$ 800.00
Single User PDF Format: US$ 800.00
Multi-User License: US$ 1,200.00
Hard Copy: US$ 900.00
CD-ROM: US$ 900.00 Diabetes has emerged as one of the most common diseases in China, affecting...
July 2011
50 pages
Asia Pacific Monthly LNG Trade & Price Database, 2010
US$ 3,500.00
Price: Hard Copy - US$ 3,750.00 Price: CD-ROM - US$ 3,750.00 Price: Electronic (e.g. PDF) - US$ 3,500.00 Price: Site Licence - US$ 7,000.00 Price: Enterprisewide - US$ 10,500.00 “Asia Pacific Monthly...
July 2011
-
China Monoclonal Antibody Industry Report, 2010-2011
US$ 1,700.00
China has been engaging in the R&D of monoclonal antibody industry for a long time, but still lags far behind the European and American countries in terms of industrialization. In 2010, the market...
July 2011
64 pages
Water Purifier Market in China 2011
US$ 475.00
The Chinese water purifier market holds significant potential for investors due to a host of drinking water contaminants plaguing the water resources of the country. Barriers to entry are low and the...
July 2011
28 pages
Biocon – Uneventful Quarter – R&D Expense Yet To Rise
US$ 140.00
BIOS 4QFY11 result was below our expectations on sales (excluding licensing income), but met our earnings estimate largely due to a lower than expected R&D expense. Licensing income too remained below estimate as it remains lumpy. Surprisingly biopharma sales (ex licensing income) grew by a modest 9% mainly ...
July 2011
6 pages
Direct-to-Home (DTH) Market in India: 2011 Edition
US$ 800.00
Direct-to-Home (DTH) is a distribution platform for multichannel TV programs on KU band by using a satellite system which transmits signal directly to the subscriber’s premises. ... satellites and content. The major players in DTH market in India are Dish TV, Tata Sky, Sun Direct, Big TV, Airtel Digital TV and ...
July 2011
40 pages
China Agriculture Investment Express_Sample
US$ 1,080.00
Agriculture is important for China, which draws Chinese Central Government's close attention. With the industrial modernization, Chinese agricultural industry is to develop to be more environmentally friendly ...
July 2011
16 pages
Research Report on China's New Energy Industry, 2011-2012
US$ 2,600.00
In 2010, China's clean energy investment grew by 30% to USD 51.10 billion. In the next few years, China's new energy industry will still be in the period of rapid development. However, in the context...
July 2011
50 pages
Bottled Water Market in China 2011
US$ 1,950.00
... players. The report begins with an overview to the bottled water market in China covering the market size and growth. It also gives a brief ... consumer concerns, domestic firms are targeting China’s premium bottled-water market and innovative market channels to promote premium brands. The competition ...
July 2011
39 pages
CADILA HEALTHCARE LTD - In a Consolidation Phase
US$ 140.00
CDH’s Q1 FY12 adjusted result (adjusted to the milestone income from Abbott) was below our sales and earnings estimate. Higher base created in FY11 by pushing product sales last year to achieve the $1b sales mark was the main reason for a muted performance in most of the business divisions. While the ...
July 2011
6 pages
Market Analysis of Pyrethroids Industry in China
US$ 8,044.00
... modes of action, pyrethroids are very well suited for future pest control. Market Analysis of Pyrethroids Industry in China is CCM International’s ... first edition report on Chinese pyrethroids industry, finished in July ...
July 2011
54 pages
Overview of Bifenthrin in China
US$ 322.00
... as termite, mosquito, cockroach, etc. Overview of Bifenthrin in China is CCM International's first edition report on Chinese bifenthrin industry, finished in July 2011. This ... (volume & value) in China, 2008-2010; Current registration situation; Prices of bifenthrin technical and formulations 2007-May 2011 ...
July 2011
14 pages
Overview of Fenpropathrin in China
US$ 322.00
... worm, diamond back moth, etc. Overview of Fenpropathrin in China is CCM International's first edition report on Chinese fenpropathrin industry, finished in July 2011. ... (volume & value) in China, 2008-2010; Current registration situation; Prices of fenpropathrin technical and formulations 2007-May 2011 ...
July 2011
11 pages
Overview of Lambda-cyhalothrin in China
US$ 322.00
... control of pests like mosquito, cockroach, etc. Overview of Lambda-cyhalothrin in China is CCM International's first edition report on Chinese lambda-cyhalothrin industry, finished in July 2011. This intelligent ...
July 2011
14 pages
China Yacht Industry Report, 2010-2012
US$ 1,500.00
China has a mainland coastline and an island coastline of 18 thousand kilometers and 14 thousand kilometers respectively. The sea areas under the jurisdiction of the PRC reach 3 million km2. Besides,...
July 2011
50 pages
China Advertising Industry Report, 2010-2011
US$ 1,800.00
The sustained economic growth ensures the healthy development of advertising industry in China. The advertising market size of China totaled RMB343.7 billion in 2010, up 22.5% from a year earlier. How...
July 2011
81 pages
China Port Industry Report, 2011
US$ 1,900.00
Benefiting from the global economic recovery, the port industry of China witnessed robust growth in 2010 after experiencing the downturn in 2009. In 2010, cargo throughput of the ports in China accomp...
July 2011
92 pages
Mirabegron Gets JP Approval – Expecting US Filing & Approval In Time!
US$ 90.00
... rating on Astellas following announcement of JP approval for Betanis / mirabegron (β3-AR agonist, overactive bladder syndrome (OAB). Mirabegron is a key strategic product for ... able to maintain its leadership in the growing OAB market. Mirabegron will be targeted for those patients who are intolerant to ...
June 2011
4 pages
Para IV Pipeline Analysis of Indian Pharma Companies
US$ 400.00
... cliff of 2014, many of the Indian companies are choosing the Para IV route to grab a higher market share, both in value and volume ... world’s top 11 products under litigation. This report is a comprehensive study of Para IV pipeline of the Indian companies and likely upside from each of the ...
June 2011
214 pages
ASTELLAS - DPP IV Royalty Sold Below Par - Another Wrong Move by the Management!
US$ 140.00
Astellas has announced to sell future royalty of DPP IV inhibitors for $609m to Royalty Pharma, which it has acquired along with OSI acquisition. We do not ... case! Presently royalty earned from marketed drugs and most advanced pipeline candidate translate into > $750m for Astellas. With modest efficacy ...
June 2011
5 pages
Asia Pacific Biotechnology Market (2008-2012)
US$ 1,600.00
Single User PDF Format: US$ 1,600.00 Multi-User License: US$ 2,400.00 Hard Copy: US$ 1,800.00 CD-ROM: US$ 1,800.00The Asia Pacific biotechnology market is one with immense potential, which can be tap...
June 2011
165 pages
China Sewage Treatment Industry Report, 2011
US$ 1,900.00
Prices: Hard Copy: US$ 2,000.00 PDF for Single User: US$ 1,900.00 PDF for Enterprisewide: US$ 3,000.00 With the advancement of industrialization in China, the sewage discharge also witnesses a risin...
June 2011
74 pages
Indian Diagnostic Market Analysis
US$ 800.00
Single User PDF Format: US$ 800.00 Multi-User License: US$ 1400.00 Hard Copy: US$ 1000.00 CD-ROM: US$ 1000.00Indian diagnostics sector is witnessing an era of immense progress in innovative competenc...
June 2011
65 pages